Published in J Oncol Pract on May 01, 2011
The economic value of personalized medicine tests: what we know and what we need to know. Genet Med (2013) 1.40
Insurance coverage policies for personalized medicine. J Pers Med (2012) 1.19
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. J Natl Compr Canc Netw (2015) 0.93
Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol (2015) 0.92
Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement. J Pers Med (2014) 0.89
A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics. Front Genet (2016) 0.75
Payer coverage policies for multigene tests. Nat Biotechnol (2017) 0.75
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med (2009) 5.69
The evidence dilemma in genomic medicine. Health Aff (Millwood) (2008) 3.58
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med (2009) 2.33
Personalized medicine: factors influencing reimbursement. Health Policy (2009) 1.90
American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol (2008) 1.75
Closing the evidence gap in the use of emerging testing technologies in clinical practice. JAMA (2008) 1.68
Realizing the promise of personalized medicine. Harv Bus Rev (2007) 1.67
Essential elements of a technology and outcomes assessment initiative. JAMA (2007) 1.63
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
Pharmacogenomics, evidence, and the role of payers. Public Health Genomics (2009) 1.26
International comparison of the definition and the practical application of health technology assessment. Int J Technol Assess Health Care (2005) 1.14
Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract (2010) 1.14
Angioplasty and stenting of the cervical carotid artery with embolic protection of the cerebral circulation. Technol Eval Cent Assess Program Exec Summ (2007) 1.13
ASCO Clinical Practice Guidelines: Past, Present and Future. J Oncol Pract (2008) 1.10
Health technology assessment in health-care decisions in the United States. Value Health (2009) 1.03
Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. J Clin Oncol (2003) 1.00
Lessons for health technology assessment: it is not only about the evidence. Value Health (2009) 0.91
Technology coverage decisions by health care plans and considerations by medical directors. Med Care (1997) 0.84
The proposed government health insurance company--no substitute for real reform. N Engl J Med (2009) 0.84
A strategic plan for integrating cost-effectiveness analysis into the US healthcare system. Am J Manag Care (2008) 0.82
Advances in pharmacogenomics technologies. Pharmacogenomics (2010) 0.80
Four health care reforms for 2009. N Engl J Med (2009) 0.79
Health technology assessment: regulators or payers--who will take the lead? Clin Ther (2008) 0.78
Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med (2005) 3.55
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer (2009) 2.63
Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United States. Med Care (2002) 2.34
Variation in access to health care for different racial/ethnic groups by the racial/ethnic composition of an individual's county of residence. Med Care (2004) 2.25
Trends in colonoscopy for colorectal cancer screening. Med Care (2007) 1.89
Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health (2007) 1.86
Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes (2014) 1.65
The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescents. Am J Public Health (2003) 1.53
Rates and predictors of colorectal cancer screening. Prev Chronic Dis (2006) 1.31
The effect of area HMO market share on cancer screening. Health Serv Res (2004) 1.29
How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ (2009) 1.27
How the new medicare drug benefit could affect vulnerable populations. Health Aff (Millwood) (2006) 1.21
How does cost matter in health-care discrete-choice experiments? Health Econ (2011) 1.15
An experiment on simplifying conjoint analysis designs for measuring preferences. Health Econ (2003) 1.14
Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract (2010) 1.14
Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med (2011) 1.07
Women's out-of-pocket expenditures and dispensing patterns for oral contraceptive pills between 1996 and 2006. Contraception (2010) 1.06
Moving beyond the typologies of managed care: the example of health plan predictors of screening mammography. Health Serv Res (2004) 1.03
A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics (2004) 1.02
A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics (2009) 1.01
Does patient cost sharing matter? Its impact on recommended versus controversial cancer screening services. Am J Manag Care (2004) 0.97
Measuring the value of pharmacogenomics. Nat Rev Drug Discov (2005) 0.97
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw (2011) 0.95
Biotechnology and Medicare's new technology policy: lessons from three case studies. Health Aff (Millwood) (2006) 0.94
Association of regional variation in primary care physicians' colorectal cancer screening recommendations with individual use of colorectal cancer screening. Prev Chronic Dis (2007) 0.92
Patient costs for medication abortion: results from a study of five clinical practices. Womens Health Issues (2006) 0.91
Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care (2004) 0.91
Is the prevalence of gatekeeping in a community associated with individual trust in medical care? Med Care (2003) 0.90
Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care (2011) 0.90
Variation in screening mammography and Papanicolaou smear by primary care physician specialty and gatekeeper plan (United States). Cancer Causes Control (2004) 0.88
Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf (2007) 0.88
Medicare formulary coverage for top-selling biologics. Nat Biotechnol (2009) 0.87
Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per Med (2009) 0.87
Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. J Oncol Pract (2012) 0.87
Colorectal cancer screening differential costs for younger versus older Americans. Am J Prev Med (2006) 0.86
Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Per Med (2010) 0.85
Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med (2011) 0.85
Angiotensin receptor blockers on the formularies of Medicare drug plans. J Gen Intern Med (2007) 0.83
Provider practice models for and costs of delivering medication abortion -- evidence from 11 US abortion care settings. Contraception (2006) 0.83
Health technology assessment and private payers's coverage of personalized medicine. Am J Manag Care (2011) 0.83
Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract (2011) 0.81
Genomic testing and therapies for breast cancer in clinical practice. Am J Manag Care (2011) 0.81
Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Res Treat (2011) 0.80
Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration. Med Care Res Rev (2006) 0.80
User characteristics and out-of-pocket expenditures for progestin-only versus combined oral contraceptives. Contraception (2012) 0.79
Private Companies Providing Health Care Price Data: Who Are They and What Information do They Provide? J Manag Care Med (2014) 0.79
Viagra and contraceptives. Health Aff (Millwood) (2003) 0.79
Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome. Am J Manag Care (2012) 0.78
Effects of simplifying choice tasks on estimates of taste heterogeneity in stated-choice surveys. Soc Sci Med (2009) 0.78
Measuring managed care and its environment using national surveys: a review and assessment. Med Care Res Rev (2006) 0.77
Evaluating the potential impact of pharmacogenomics on ADRs. J Manag Care Pharm (2003) 0.75
Insured women and payment for elective abortion. Womens Health Issues (2008) 0.75
Willingness to recommend a health plan: who is dissatisfied and what don't they like? Am J Manag Care (2004) 0.75
A qualitative study of insurers' coverage for mifepristone-induced abortion. Manag Care Interface (2005) 0.75
Protocols for pediatric poisonings from nontoxic substances: are they valid? Pediatr Emerg Care (2006) 0.75